Long term effectiveness of low dose mithramycin for paget's disease of bone
Open Access
- 1 March 1979
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 22 (3) , 215-218
- https://doi.org/10.1002/art.1780220302
Abstract
Nineteen patients with Paget's disease of bone were studied 7 months to 5 years after therapy with mithramycin in a dose averaging 11.5 μg/kg body weight daily for 10 days. Thirteen patients, including 3 with the longest followup intervals, remained free of pain. Objective measures of disease activity (serum alkaline phosphatase level and 99mtechnetium pyrophosphate bone scan) were less favorable. There was no evidence of long term toxicity.This publication has 11 references indexed in Scilit:
- Paget's disease of bone.BMJ, 1977
- Diphosphonate Therapy of Paget's Disease of BoneJournal of Clinical Endocrinology & Metabolism, 1977
- The scintigraphic findings in Paget's disease of boneClinical Radiology, 1976
- Outpatient Treatment of Paget's Disease of Bone with MithramycinAnnals of Internal Medicine, 1974
- A passel of "pseudo's"JAMA, 1973
- Mithramycin in the Treatment of Pagetʼs Disease of BoneJournal of Bone and Joint Surgery, 1972
- Glucagon in the Treatment of Paget's Disease of BoneBMJ, 1971
- Treatment of Paget's Disease of Bone with MithramycinBMJ, 1971
- Experiences in the Treatment of Paget's Disease of Bone With MithramycinJAMA, 1970
- Effects of Mithramycin on Paget's Disease of BoneAnnals of Internal Medicine, 1969